We can’t show the full text here under this license. Use the link below to read it at the source.
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease
Health outcomes in new users of SGLT2 inhibitors or GLP-1 receptor agonists with type 2 diabetes and chronic kidney disease
AI simplified
Abstract
A total of 54,308 patients with and initiated sodium-glucose cotransporter-2 inhibitors (SGLT2i) across various health databases.
- Crude incidence rates of kidney and heart failure were generally higher in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) cohorts compared to SGLT2i cohorts.
- The study included data from multiple sources, including Danish National Health Registers and US Optum Electronic Health Records.
- Baseline clinical profile differences were identified between new users of SGLT2i and GLP-1 RA.
- The incidence of kidney failure and cardiovascular outcomes in patients receiving these antidiabetic medications is important for future comparisons of CKD treatments.
AI simplified
Key numbers
1.20 events per 1000 PY
Kidney Failure ()
during follow-up in the cohort.
15.19/1000 PY
Atrial Fibrillation ()
Most common cardiovascular outcome in the cohort.
0.27–8.88 events per 1000 PY
Kidney Failure ()
Incidence rates of kidney failure in the cohort across data sources.